- Home
- LPX vs TFX Comparison
LPX vs TFX Comparison
Compare LPX & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPX | TFX |
|---|---|---|
| Founded | 1973 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.6B |
| IPO Year | 1994 | 1994 |
Fundamental Metrics
Financial Performance| Metric | LPX | TFX |
|---|---|---|
| Price | $75.80 | $107.22 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 9 |
| Target Price | $110.17 | ★ $140.25 |
| AVG Volume (30 Days) | ★ 1.1M | 866.0K |
| Earning Date | 05-20-2026 | 05-27-2026 |
| Dividend Yield | ★ 1.59% | 1.26% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.08 | N/A |
| Revenue | ★ $2,708,000,000.00 | $1,992,713,000.00 |
| Revenue This Year | N/A | $46.78 |
| Revenue Next Year | $11.10 | $3.86 |
| P/E Ratio | $36.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $73.42 | $100.18 |
| 52 Week High | $102.86 | $143.32 |
Technical Indicators
Market Signals| Indicator | LPX | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 33.04 | 41.21 |
| Support Level | $73.42 | $102.03 |
| Resistance Level | $93.71 | $125.12 |
| Average True Range (ATR) | 2.87 | 4.18 |
| MACD | -0.70 | -1.14 |
| Stochastic Oscillator | 11.20 | 6.30 |
Price Performance
Historical ComparisonAbout LPX Louisiana-Pacific Corporation
Louisiana-Pacific is primarily an oriented strand board producer and also offers engineered wood siding used in home construction and repair and remodel projects. The company is largely exposed to the North American housing market but has also established capacity in Brazil and Chile.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.